Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 25;29(23):5550.
doi: 10.3390/molecules29235550.

Synthesis of 1,2,4-Oxadiazin-5(6 H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors

Affiliations

Synthesis of 1,2,4-Oxadiazin-5(6 H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors

Sofia I Presnukhina et al. Molecules. .

Abstract

Monoamine oxidase (MAO) plays a key role in the pathogenesis of central nervous system disorders, and MAO inhibitors have been used in the treatment of depression and Parkinson's disease. In the search for new classes of MAO inhibitors, the present study investigated a series of 1,2,4-oxadiazin-5(6H)-one derivatives. This study provides the first optimization of the reaction conditions for the condensation of amidoximes with alkyl 2-halocarboxylates to yield the desired 1,2,4-oxadiazin-5(6H)-ones. The results of the in vitro MAO inhibition studies showed that the 1,2,4-oxadiazin-5(6H)-ones were indeed inhibitors of human MAO with the most potent inhibition observed for 5f (IC50 = 0.900 µM) and 7c (IC50 = 0.371 µM). It was concluded that, with appropriate substitution, 1,2,4-oxadiazin-5(6H)-one derivatives would act as good potency MAO-B inhibitors and lead compounds for the development of antiparkinsonian drugs. In Parkinson's disease, MAO-B inhibitors enhance central dopamine levels and reduce MAO-mediated production of hydrogen peroxide and resultant oxidative injury. This study represents one of few works to investigate synthetic approaches and biological activities of the 1,2,4-oxadiazin-5(6H)-one class of heterocycles.

Keywords: MAO; Parkinson’s disease; inhibition; monoamine oxidase; oxadiazine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The structures of selected MAO inhibitors.
Scheme 1
Scheme 1
Reactions of amidoximes 1 with 2-halocarboxylate 2 in a t-BuONa–DMSO medium (top panel); single-crystal XRD structures of products 3a and 5b (side panel). Conditions: 1 (2 mmol), 2 (2.4 mmol), t-BuONa (4 mmol), DMSO (3 mL), RT, 18 h. Isolated yields are presented.
Scheme 2
Scheme 2
Synthesis of compounds 68 via reactions of amidoximes 1 with dimethyl maleate.
Figure 2
Figure 2
Plots of the activities of MAO-A (A) and MAO-B (B) in the presence of selected inhibitors. These plots were used to estimate IC50 values. Each data point represents the mean ± standard deviation (SD) of triplicate measurements.
Figure 3
Figure 3
Lineweaver–Burk plots for the inhibition of MAO-A (A) and MAO-B (B) by 3f and 5f, respectively. The insets are replots of the slopes of the Lineweaver–Burk plots versus the concentration of the inhibitor. The legends indicate the inhibitor concentrations used.
Figure 4
Figure 4
The binding orientations (R)-5f (cyan) and (S)-5f (magenta) to the active site of MAO-B. The surface indicates the active site cavity, while dashed lines indicate hydrogen bonds.

Similar articles

References

    1. Edmondson D.E., Binda C., Wang J., Upadhyay A.K., Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry. 2009;48:4220–4230. doi: 10.1021/bi900413g. - DOI - PMC - PubMed
    1. Ramsay R. Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 2012;12:2189–2209. doi: 10.2174/156802612805219978. - DOI - PubMed
    1. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 1999;22:197–217. doi: 10.1146/annurev.neuro.22.1.197. - DOI - PMC - PubMed
    1. Binda C., Newton-Vinson P., Hubálek F., Edmondson D.E., Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002;9:22–26. doi: 10.1038/nsb732. - DOI - PubMed
    1. Son S.-Y., Ma J., Kondou Y., Yoshimura M., Yamashita E., Tsukihara T. Structure of human monoamine oxidase A at 2.2 Å resolution: The control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. USA. 2008;105:5739–5744. doi: 10.1073/pnas.0710626105. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources